BioCryst Announced Data Showing Reductions In Attack Rates In HAE Patients With Normal C1-Inhibitor After Beginning ORLADEYO Treatment
BioCryst Announced Data Showing Reductions In Attack Rates In HAE Patients With Normal C1-Inhibitor After Beginning ORLADEYO Treatment
BioCryst 公佈的數據顯示，在開始 ORLADEYO 治療後，使用正常 C1 抑制劑的 HAE 患者的發作率有所降低
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction in monthly attack rates after starting oral, once-daily ORLADEYO (berotralstat). The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain.
BioCryst Pharmaceuticals, Inc.（納斯達克股票代碼：BCRX）今天公佈了新的現實證據，表明C1抑制劑（HAE-NC1-INH）水平和功能正常的遺傳性血管性水腫（HAE）患者在開始口服、每日一次的ORLADEYO（berotralstat）後，每月發作率有所降低。這些數據已在西班牙瓦倫西亞舉行的歐洲過敏與臨床免疫學學會（EAACI）大會上公佈。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。